PIK3CA mutation and clinicopathological features of colorectal cancer: a systematic review and Meta-Analysis

References

• Siegel RL, Miller KD, Fedewa SA. Colorectal cancer statistics, 2017. CA Cancer J Clin. 2017;67(3):177–193.
   PubMed Web of Science ®Google Scholar
• Cathomas G. PIK3CA in colorectal cancer. Front Oncol. 2014;4:35
   PubMedGoogle Scholar
• Samuels Y, Diaz LA, Jr Schmidt-Kittler O, et al. Mutant PIK3CA promotes cell growth and invasion of human cancer cells. Cancer Cell. 2005;7(6):561–573.
   PubMed Web of Science ®Google Scholar
• Shaw RJ, Cantley LC. Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature. 2006;441(7092):424
   PubMed Web of Science ®Google Scholar
• Ogino S, Lochhead P, Giovannucci E, et al. Discovery of colorectal cancer PIK3CA mutation as potential predictive biomarker: power and promise of molecular pathological epidemiology. Oncogene. 2014;33(23):2949.
   PubMed Web of Science ®Google Scholar
• Mao C, Yang Z, Hu X, et al. PIK3CA exon 20 mutations as a potential biomarker for resistance to anti-EGFR monoclonal antibodies in KRAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis. Ann Oncol. 2012;23(6):1518–1525.
   PubMed Web of Science ®Google Scholar
• Nosho K, Kawasaki T, Longtine JA, et al. PIK3CA mutation in colorectal cancer: relationship with genetic and epigenetic alterations. Neoplasia. 2008;10(6):534–541.
   PubMed Web of Science ®Google Scholar
• Velho S, Oliveira C, Ferreira A, et al. The prevalence of PIK3CA mutations in gastric and colon cancer. Eur J Cancer. 2005;41(11):1649–1654.
   PubMed Web of Science ®Google Scholar
• Liao X, Lochhead P, Nishihara R, et al. Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival. N Engl J Med. 2012;367(17):1596–1606.
   PubMed Web of Science ®Google Scholar
• Manceau G, Marisa L, Boige V, et al. PIK3CA mutations predict recurrence in localized microsatellite stable colon cancer. Cancer Med. 2015;4(3):371–382.
   PubMed Web of Science ®Google Scholar
• Zhu K, Yan H, Wang R, et al. Mutations of KRAS and PIK3CA as independent predictors of distant metastases in colorectal cancer. Med Oncol. 2014;31(7):16.
   PubMed Web of Science ®Google Scholar
• He Y, Van't Veer LJ, Mikolajewska-Hanclich I, et al. PIK3CA mutations predict local recurrences in rectal cancer patients. Clin Cancer Res. 2009;15(22):6956–6962. CCR-09-1165.
   PubMed Web of Science ®Google Scholar
• Phipps AI, Makar KW, Newcomb PA. Descriptive profile of PIK3CA-mutated colorectal cancer in postmenopausal women. Int J Colorectal Dis. 2013;28(12):1637–1642.
   PubMed Web of Science ®Google Scholar
• Liao X, Morikawa T, Lochhead P, et al. Prognostic role of PIK3CA mutation in colorectal cancer: cohort study and literature review. Clin Cancer Res. 2012;18(8):2257–2268.
   PubMed Web of Science ®Google Scholar
• Ogino S, Liao X, Imamura Y, et al. Predictive and prognostic analysis of PIK3CA mutation in stage III colon cancer intergroup trial. J Natl Cancer Inst. 2013;105(23):1789–1798.
   PubMedGoogle Scholar
• Wang Q, Shi Y-L, Zhou K, et al. PIK3CA mutations confer resistance to first-line chemotherapy in colorectal cancer. Cell Death Dis. 2018;9(7):739.
   PubMed Web of Science ®Google Scholar
• Day FL, Jorissen RN, Lipton L, et al. PIK3CA and PTEN gene and exon mutation-specific clinicopathological and molecular associations in colorectal cancer. Clin Cancer Res. 2013;19(12):3285. clincanres. 3614.2012.
   PubMed Web of Science ®Google Scholar
• Zhao L, Vogt PK. Helical domain and kinase domain mutations in p110α of phosphatidylinositol 3-kinase induce gain of function by different mechanisms. P Natl A Sci USA. 2008;105(7):2652–2657.
   PubMed Web of Science ®Google Scholar
• Kalinsky K, Jacks LM, Heguy A, et al. PIK3CA mutation associates with improved outcome in breast cancer. Clin Cancer Res. 2009;15(16):5049–5059. CCR-09-0632.
   PubMed Web of Science ®Google Scholar
• Lai Y-L, Mau B-L, Cheng W-H, et al. PIK3CA exon 20 mutation is independently associated with a poor prognosis in breast cancer patients. Ann Surg Oncol. 2008;15(4):1064–1069.
   PubMed Web of Science ®Google Scholar
• McCleary NJ, Sato K, Nishihara R, et al. Prognostic utility of molecular factors by age at diagnosis of colorectal cancer. Clin Cancer Res. 2016;22(6):1489–1498.
   PubMed Web of Science ®Google Scholar
• Chen J, Guo F, Shi X, et al. BRAF V600E mutation and KRAS codon 13 mutations predict poor survival in Chinese colorectal cancer patients. BMC Cancer. 2014;14(1):802.
   PubMed Web of Science ®Google Scholar
• Guo F, Gong H, Zhao H, et al. Mutation status and prognostic values of KRAS, NRAS, BRAF and PIK3CA in 353 Chinese colorectal cancer patients. Sci Rep. 2018;8(1):6076.
   PubMed Web of Science ®Google Scholar
• Weidlich S, Walsh K, Crowther D, et al. Pyrosequencing-based methods reveal marked inter-individual differences in oncogene mutation burden in human colorectal tumours. Br J Cancer. 2011;105(2):246.
   PubMed Web of Science ®Google Scholar
• Mao C, Zhou J, Yang Z, et al. KRAS, BRAF and PIK3CA mutations and the loss of PTEN expression in Chinese patients with colorectal cancer. PloS one. 2012;7(5):e36653
   PubMed Web of Science ®Google Scholar
• Birgisson H, Edlund K, Wallin U, et al. Microsatellite instability and mutations in BRAF and KRAS are significant predictors of disseminated disease in colon cancer. BMC Cancer. 2015;15(1):125.
   PubMed Web of Science ®Google Scholar
• Sarasqueta AF, Zeestraten EC, van Wezel T, et al. PIK3CA kinase domain mutation identifies a subgroup of stage III colon cancer patients with poor prognosis. Cell Oncol. 2011;34(6):523–531.
   Web of Science ®Google Scholar
• Garrido-Laguna I, Hong DS, Janku F, et al. KRASness and PIK3CAness in patients with advanced colorectal cancer: outcome after treatment with early-phase trials with targeted pathway inhibitors. PLoS One. 2012;7(5):e38033.
   PubMed Web of Science ®Google Scholar
• Vogelaar FJ, van Erning FN, Reimers MS, et al. The prognostic value of Microsatellite Instability, KRAS, BRAF and PIK3CA mutations in stage II colon cancer patients. Mol Med. 2015;21(1):1038.
   Web of Science ®Google Scholar
• Stec R, Semeniuk-Wojtaś A, Charkiewicz R, et al. Mutation of the PIK3CA gene as a prognostic factor in patients with colorectal cancer. Oncology letters. 2015;10(3):1423–1429.
   PubMed Web of Science ®Google Scholar
• Shen Y, Wang J, Han X, et al. Effectors of epidermal growth factor receptor pathway: the genetic profiling of KRAS, BRAF, PIK3CA, NRAS mutations in colorectal cancer characteristics and personalized medicine. PloS one. 2013;8(12):e81628.
   PubMed Web of Science ®Google Scholar
• Phipps AI, Ahnen DJ, Cheng I, et al. PIK3CA somatic mutation status in relation to patient and tumor factors in racial/ethnic minorities with colorectal cancer. Cancer Epidemiol Biomar. 2015;24(7):1046–1051.
   PubMed Web of Science ®Google Scholar
• Palomba G, Colombino M, Contu A, et al. Prevalence of KRAS, BRAF, and PIK3CA somatic mutations in patients with colorectal carcinoma may vary in the same population: clues from Sardinia. J Transl Med. 2012;10(1):178.
   PubMed Web of Science ®Google Scholar
• Murphy C, Turner N, Wong HL, et al. Examining the impact of regular aspirin use and PIK3CA mutations on survival in stage 2 colon cancer. Intern Med J. 2017;47(1):88–98.
   PubMed Web of Science ®Google Scholar
• Lin J-K, Lin P-C, Lin C-H, et al. Clinical relevance of alterations in quantity and quality of plasma DNA in colorectal cancer patients: based on the mutation spectra detected in primary tumors. Ann Surg Oncol. 2014;21(S4):680–686.
   Web of Science ®Google Scholar
• Li Z-Z, Wang F, Zhang Z-C, et al. Mutation profiling in chinese patients with metastatic colorectal cancer and its correlation with clinicopathological features and anti-EGFR treatment response. Oncotarget. 2016;7(19):28356.
   PubMedGoogle Scholar
• Li H-T, Lu Y-Y, An Y-X, et al. KRAS, BRAF and PIK3CA mutations in human colorectal cancer: relationship with metastatic colorectal cancer. Oncol Rep. 2011;25(6):1691–1697.
   PubMed Web of Science ®Google Scholar
• Kato S, Iida S, Higuchi T, et al. PIK3CA mutation is predictive of poor survival in patients with colorectal cancer. Int J Cancer. 2007;121(8):1771–1778.
   PubMed Web of Science ®Google Scholar
• Iida S, Kato S, Ishiguro M, et al. PIK3CA mutation and methylation influences the outcome of colorectal cancer. Oncol Lett. 2012;3(3):565–570.
   PubMed Web of Science ®Google Scholar
• Gavin P, Colangelo LH, Fumagalli D, et al. Mutation profiling and microsatellite instability in stage II and III colon cancer: an assessment of their prognostic and oxaliplatin predictive value. Clin Cancer Res. 2012;18(23):6531. clincanres. 0605.2012.
   PubMed Web of Science ®Google Scholar
• Domingo E, Church DN, Sieber O, et al. Evaluation of PIK3CA mutation as a predictor of benefit from nonsteroidal anti-inflammatory drug therapy in colorectal cancer. J Clin Oncol. 2013;31(34):4297–4305.
   PubMed Web of Science ®Google Scholar
• Corso G, Pascale V, Flauti G, et al. Oncogenic mutations and microsatellite instability phenotype predict specific anatomical subsite in colorectal cancer patients. Eur J Hum Genet. 2013;21(12):1383.
   PubMed Web of Science ®Google Scholar
• Christensen TD, Palshof JA, Larsen FO, et al. Associations between primary tumor RAS, BRAF and PIK3CA mutation status and metastatic site in patients with chemo-resistant metastatic colorectal cancer. Acta Oncologica. 2018;57(8):1057–1062.
   PubMed Web of Science ®Google Scholar
• Chang S-C, Lin P-C, Lin J-K, et al. Mutation spectra of common cancer-associated genes in different phenotypes of colorectal carcinoma without distant metastasis. Ann Surg Oncol. 2016;23(3):849–855.
   PubMed Web of Science ®Google Scholar
• Whitehall VL, Rickman C, Bond CE, et al. Oncogenic PIK3CA mutations in colorectal cancers and polyps. Int J Cancer. 2012;131(4):813–820.
   PubMed Web of Science ®Google Scholar
• Abubaker J, Bavi P, Al-Harbi S, et al. Clinicopathological analysis of colorectal cancers with PIK3CA mutations in Middle Eastern population. Oncogene. 2008;27(25):3539.
   PubMed Web of Science ®Google Scholar
• Barault L, Veyrie N, Jooste V, et al. Mutations in the RAS‐MAPK, PI (3) K (phosphatidylinositol‐3‐OH kinase) signaling network correlate with poor survival in a population‐based series of colon cancers. Int J Cancer. 2008;122(10):2255–2259.
   PubMed Web of Science ®Google Scholar
• Ganesan P, Janku F, Naing A, et al. Target-based therapeutic matching in early-phase clinical trials in patients with advanced colorectal cancer and PIK3CA mutations. Mol Cancer Ther. 2013;12(12):2857.
   PubMed Web of Science ®Google Scholar
• Nam SK, Yun S, Koh J, et al. BRAF, PIK3CA, and HER2 oncogenic alterations according to KRAS mutation status in advanced colorectal cancers with distant metastasis. PloS one. 2016;11(3):e0151865.
   PubMed Web of Science ®Google Scholar
• Al-Shamsi HO, Jones J, Fahmawi Y, et al. Molecular spectrum of KRAS, NRAS, BRAF, PIK3CA, TP53, and APC somatic gene mutations in Arab patients with colorectal cancer: determination of frequency and distribution pattern. J Gastrointest Oncol. 2016;7(6):882.
   PubMed Web of Science ®Google Scholar
• Balc’h EL, Grandin N, Demattei M-V, et al. Measurement of telomere length in colorectal cancers for improved molecular diagnosis. IJMS. 2017;18(9):1871.
   Web of Science ®Google Scholar
• Chiu JW, Krzyzanowska MK, Serra S, et al. Molecular profiling of patients with advanced colorectal cancer: princess margaret cancer centre experience. Clin Colorectal Canc. 2018;17(1):73–79.
   PubMed Web of Science ®Google Scholar
• Russo AL, Borger DR, Szymonifka J, et al. Mutational analysis and clinical correlation of metastatic colorectal cancer. Cancer. 2014;120(10):1482–1490.
   PubMed Web of Science ®Google Scholar
• Eklöf V, Wikberg ML, Edin S, et al. The prognostic role of KRAS, BRAF, PIK3CA and PTEN in colorectal cancer. Br J Cancer. 2013;108(10):2153.
   PubMed Web of Science ®Google Scholar
• Neumann J, Wehweck L, Maatz S, et al. Alterations in the EGFR pathway coincide in colorectal cancer and impact on prognosis. Virchows Arch. 2013;463(4):509–523.
   PubMed Web of Science ®Google Scholar
• Zhang J, Zheng J, Yang Y, et al. Molecular spectrum of KRAS, NRAS, BRAF and PIK3CA mutations in Chinese colorectal cancer patients: analysis of 1,110 cases. Sci Rep. 2015;5(1):18678.
   PubMed Web of Science ®Google Scholar
• Fadhil W, Kindle K, Jackson D, et al. DNA content analysis of colorectal cancer defines a distinct ‘microsatellite and chromosome stable’group but does not predict response to radiotherapy. Int J Exp Path. 2014;95(1):16–23.
   PubMed Web of Science ®Google Scholar
• Mei Z, Duan C, Li C, et al. Prognostic role of tumor PIK3CA mutation in colorectal cancer: a systematic review and meta-analysis. Ann Oncol. 2016;27(10):1836–1848.
   PubMed Web of Science ®Google Scholar
• De Roock W, Claes B, Bernasconi D, et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol. 2010;11(8):753–762.
   PubMed Web of Science ®Google Scholar
• Oda K, Okada J, Timmerman L, et al. PIK3CA cooperates with other phosphatidylinositol 3′-kinase pathway mutations to effect oncogenic transformation. Cancer Res. 2008;68(19):8127–8136.
   PubMed Web of Science ®Google Scholar
• Guinney J, Dienstmann R, Wang X, et al. The consensus molecular subtypes of colorectal cancer. Nat Med. 2015;21(11):1350.
   PubMed Web of Science ®Google Scholar
• Smeby J, Sveen A, Merok M, et al. CMS-dependent prognostic impact of KRAS and BRAF V600E mutations in primary colorectal cancer. Ann Oncol. 2018;29(5):1227–1234.
   PubMed Web of Science ®Google Scholar
• Mohamed A, Twardy B, AbdAllah N, et al. Clinical impact of PI3K/BRAF mutations in RAS wild metastatic colorectal cancer: Meta-analysis results. J Gastrointest Canc. 2019;50(2):269–275.
   PubMed Web of Science ®Google Scholar
• Maus MK, Hanna DL, Stephens CL, et al. Distinct gene expression profiles of proximal and distal colorectal cancer: implications for cytotoxic and targeted therapy. Pharmacogenomics J. 2015;15(4):354.
   PubMed Web of Science ®Google Scholar
• Hugen N, Brown G, Glynne-Jones R, et al. Advances in the care of patients with mucinous colorectal cancer. Nat Rev Clin Oncol. 2016;13(6):361.
   PubMed Web of Science ®Google Scholar